[Form 4] Axogen, Inc. Insider Trading Activity

Axogen, Inc. director Kathy Johnson Weiler exercised options to acquire 16,344 shares of common stock at $6.95 per share, then sold the same 16,344 shares in an open‑market transaction at a weighted average price of $44.091 per share on May 7, 2026.

Rhea-AI Filing Summary

Axogen, Inc. director Kathy Johnson Weiler exercised options to acquire 16,344 shares of common stock at $6.95 per share, then sold the same 16,344 shares in an open‑market transaction at a weighted average price of $44.091 per share on May 7, 2026.

Following these transactions, she reports holding no common shares directly but retains 27,307 employee stock options with a $6.95 exercise price expiring on December 20, 2033. According to the grant terms, these options vest in three equal annual installments beginning on December 20, 2024.

Insider Trade Summary

Exercise and Sale: 16,344 shares ($607K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Weiler Kathy Johnson

Role Director

Sold 16,344 shs ($721K)

Approx. gross sale proceeds $721K

Approx. exercise cost $114K

Approx. pre-tax spread $607K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to purchase)	16,344	$0.00	$0.00
Exercise	Common Stock	16,344	$6.95	$114K
Sale	Common Stock	16,344	$44.091	$721K

Holdings After Transaction: Employee Stock Option (right to purchase) — 27,307 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.04 to $44.26 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 20, 2024.

Key Figures

Shares sold: 16,344 shares Sale price (weighted average): $44.091 per share Options exercised: 16,344 shares at $6.95 +1 more

4 metrics

Shares sold 16,344 shares Open-market sale on May 7, 2026

Sale price (weighted average) $44.091 per share Common stock sale range $44.04–$44.26

Options exercised 16,344 shares at $6.95 Employee stock option exercise into common stock

Remaining stock options 27,307 options at $6.95 Expire December 20, 2033

Key Terms

weighted average sale price, Employee Stock Option (right to purchase), Exercise or conversion of derivative security, vest in three equal annual installments

4 terms

weighted average sale price financial

"The reported price in Column 4 is a weighted average sale price."

Employee Stock Option (right to purchase) financial

"security_title: "Employee Stock Option (right to purchase)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

vest in three equal annual installments financial

"Options vest in three equal annual installments on the annual anniversary of the grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Axogen (AXGN) report for Kathy Johnson Weiler?

Axogen (AXGN) reported that director Kathy Johnson Weiler exercised options for 16,344 common shares at $6.95 each and sold all 16,344 shares in an open-market transaction at a weighted average price of $44.091 per share on May 7, 2026.

How many Axogen (AXGN) shares did Kathy Johnson Weiler sell and at what price?

Kathy Johnson Weiler sold 16,344 Axogen (AXGN) common shares in an open‑market transaction at a weighted average price of $44.091 per share, with individual trade prices ranging from $44.04 to $44.26, as disclosed in the filing footnote.

What options did Kathy Johnson Weiler exercise in the Axogen (AXGN) Form 4 filing?

She exercised employee stock options covering 16,344 Axogen (AXGN) common shares at an exercise price of $6.95 per share. These options were part of a board service grant and were converted into common stock before being sold the same day.

What Axogen (AXGN) equity position does Kathy Johnson Weiler hold after these transactions?

After the reported transactions, she holds no Axogen (AXGN) common stock directly. She retains 27,307 employee stock options with a $6.95 exercise price, scheduled to expire on December 20, 2033, according to the option grant’s disclosed terms.

How do Kathy Johnson Weiler’s Axogen (AXGN) options vest over time?

The Axogen (AXGN) options were granted for joining the board and vest in three equal annual installments on each anniversary of the grant date, with the first vesting date on December 20, 2024, as specified in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weiler Kathy Johnson

(Last) (First) (Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA FLORIDA 32615

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026	05/07/2026	M		16,344	A	$6.95	16,344	D
Common Stock	05/07/2026	05/07/2026	S		16,344	D	$44.091(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to purchase)	$6.95	05/07/2026	05/07/2026	M			16,344	(2)	12/20/2033	Common Stock	16,344	$0	27,307	D

Explanation of Responses:

1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.04 to $44.26 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 20, 2024.

Remarks:

	/s/ Marc Began, as attorney-in-fact for Kathy Weiler	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)